Background: The Australian/Canadian Osteoarthritis Hand Index (AUSCAN) and Patient-Rated Wrist-Hand Evaluation (PRWHE) are 2 patient-related outcome measures to assess pain and disability in patients with osteoarthritis (OA). The purpose of this study was to evaluate the AUSCAN and PRWHE in a large-scale, longitudinal cohort of patients with early thumb carpometacarpal (CMC) OA. Methods: We obtained baseline data on 135 individuals (92 with early CMC OA participants and 43 asymptomatic controls) and at follow-up (year 1.5) on 83 individuals. We assessed the internal consistency using Cronbach alpha, and construct and criterion validity using other pain scales and objective measures of strength, respectively. We also examined the correlation between the AUSCAN and PRWHE and correlation coefficients at baseline and follow-up, as well as the correlation between changes in these instruments over the follow-up period. Results: Internal consistency was high for both AUSCAN and PRWHE totals and subscales (Cronbach α > 0.70). Both instruments demonstrated construct validity compared with the Verbal Rating Scale (r = 0.52-0.60, P < .01), an assessment of pain, and moderate criterion validity compared with key pinch and grip strength (r = −.24 to −.33, P < .05). These instruments were highly correlated with each other at baseline and follow-up time points (r = 0.76−.94, P < .01), and changes in a patient's total scores over time were also correlated (r = 0.83, P < .01). Conclusions: The AUSCAN and PRWHE are both valid assessments for pain and/or disability in patients with early thumb CMC OA.
Introduction
Thumb carpometacarpal (CMC) osteoarthritis (OA) is a common disease affecting up to 11% and 33% of men and women, respectively, between the ages 50 and 60 and up to 90% over the age of 80. 3, 12 The progression of thumb CMC OA results in pain, reduced strength, and functional impairment. 9 Variable operative and nonoperative treatments exist to relieve symptoms, restore strength and function, and slow the progression of the disease. 19, 32 Self-reported outcome measures are important components of the patient assessment during hand therapy, nonsurgical management, and surgical treatment of CMC OA. 21 Several patient self-report scales have been developed for the upper extremity, including the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) 1, 4 ; the Patient-Rated WristHand Evaluation (PRWHE) 28 ; the Arthritis Hand Function Test (AHFT) 2 ; the Cochin Hand Function Scale 29 ; the Functional Index for Hand Osteoarthritis (FIHOA); the Disabilities of the Arm, Shoulder and Hand (DASH) 8, 13, 22 ; and the Michigan Hand Questionnaire (MHQ). 7 ,31 A provider's choice of instrument depends on its reliability for a given population, responsiveness in detecting clinically important changes, and practicality with respect to time, money, and ease of use. 1 Stanford University, CA, USA 2 Brown University, Providence, RI, USA The AUSCAN 4 is a 15-item scale measuring pain (5 items), stiffness (1 item), and function (9 items) during the preceding 48 hours. AUSCAN scores, described in detail by Bellamy and colleagues, 5 have total scores that range from 0 to 60, pain subscales that range from 0 to 20, stiffness subscales that range from 0 to 4, and function subscales that range from 0 to 36; higher scores indicate a greater level of intensity. The PRWHE is a 15-item scale that addresses pain and disability related to wrist and hand disorders during the preceding 2 weeks, similarly with higher scores indicating worse pain or disability. The score ranges from 0 to 100 points; 50 points are allocated to 5 pain items and 50 points to 10 functional items, with the total score being a simple sum of these subscales. One supplemental question on appearance of the affected hand is scored separately. Previous studies have shown that both the AUSCAN and PRWHE have acceptable internal consistency, construct validity, factorial validity, and responsiveness for patients with moderate to advanced hand and thumb CMC OA. 1, 4, 5, 21, 22, 26 This study utilized the AUSCAN and PRWHE to assess self-reported pain and disability in a cohort of participants with early thumb CMC OA. While previous studies have compared the AUSCAN and PRWHE in end-stage CMC OA following tendon interposition arthroplasty, 21, 23 no studies exist that have compared these instruments in patients with early thumb CMC OA who are followed on a longitudinal basis as they develop more advanced OA. Self-report instruments that have been validated only in end-stage disease may not be reliable in participants with early OA: The instrument may not be sensitive enough to detect clinically significant differences in early disease. 21 The purpose of this study was to examine the internal consistency, construct validity, and criterion validity of the AUSCAN and PRWHE, over time, in a population with early CMC OA. 14, 15, 20, 25 We also conducted hypothesis testing to determine whether these instruments were correlated with each other at baseline and follow-up. We hypothesized that (1) the AUSCAN and PRWHE would be internally consistent in measuring pain and function at baseline and follow-up visits; (2) they would demonstrate construct and criterion validity with other pain scales and objective measures of hand strength, respectively; and (3) scores from these instruments would be highly correlated with each other in a cohort with early thumb CMC OA.
Materials and Methods

Study Design and Participants
Participants with early CMC OA and asymptomatic controls were recruited prospectively in a larger study investigating the thumb CMC joint. 14, 15, 20, 25 Baseline (year 0) tests were conducted on 135 individuals (92 early OA and 43 controls), and follow-up tests (after 1.5 years) were conducted on 83 of the early OA participants with 9 lost to follow-up or progressing to surgery. Analysis of the properties of the instruments was restricted to the early OA cohort, which included the 92 individuals at baseline and 83 at follow-up. Data analysis was conducted 2.5 years after patients were enrolled.
The study was performed at secondary-care referral facilities, Stanford University and Brown University, and prior institutional review board (IRB) approval was obtained at both sites. Participants were consented prior to data collection, and radiographs and participant history were used to determine inclusion and exclusion criteria for participants. Age-matched controls were recruited based on convenience and/or unrelated contralateral hand complaints that did not fulfill exclusion criteria.
Inclusion criteria of early OA participants included both pain or discomfort complaints at the base of the thumb and radiographs rated as modified Eaton score 0 or 1 by senior hand surgeons (A.L.L. and A.-P.C.W.). 10, 11, 18 Exclusion criteria included rheumatoid arthritis, any inflammatory joint disease, connective tissue disease, metabolic bone disease, history of wrist and thumb fractures, ligamentous injury, or prior significant ipsilateral hand surgery. 25 AUSCAN and PRWHE surveys were administered during both baseline and follow-up visits. All patients agreed to complete the surveys, any skipped items were omitted from the analysis and the average number of missing items was reported for each subscale (Table 1) .
Data Analysis
This study adhered to the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) guidelines for the critical appraisal of health measurement properties and patient-reported outcomes. 27 Prior to testing the measurement properties of the self-report measures in the OA cohort, we first compared their AUSCAN and PRWHE scores with the control group to assure that there were detectable differences in patients with early disease versus asymptomatic controls. Means, standard deviations, and ranges were calculated to examine the distributions of the scores of each instrument. Student's t tests were conducted to compare test scores for controls and symptomatic participants and to determine whether the mean change in scores between baseline and follow-up was statistically significant.
Thereafter, we assessed the internal consistency of the AUSCAN and PRWHE totals as well as individual subscales for the OA cohort at baseline and 1.5-year follow-up. Per COSMIN guidelines, we first used a factor analysis to confirm the unidimensionality of each subscale and the adequacy of sample size. In terms of statistical methods, we then used Cronbach's alpha to measure internal consistency, which we defined as the degree of interrelatedness between the items within a given scale or subscale.
To examine construct validity, the degree to which the instrument measures the construct being measured, we compared the pain subscale of each tool with a Verbal Rating Scale (VRS) measurement of pain. The VRS was measured as the sum of the pain during pinching, grasping, twisting, and occupational and avocational tasks measured from 0 to 50, with 0 being the lowest and 50 the highest 16 ; this comparison was used to assess how accurately the AUSCAN and PRWHE measured this concept of "pain." Criterion validity was assessed using the similar COSMIN guidelines, comparing the function subscales of the AUS-CAN and the PRWHE with a "gold standard" objective measurement of strength. We measured key pinch and grip strength on a Greenleaf Sensor (Greenleaf Medical Systems, Palo Alto, California). Key pinch was obtained by holding the sensor between the thumb and the radial aspect of the first digit near the proximal interphalangeal joint. Grip strength was measured with the elbow flexed at 90°, wrist in neutral position, with the thumb parallel to the 4 digits around an instrumented digital dynamometer. The maximum measurements of three independent tests were averaged to calculate the pinch and grip variables.
To further assess construct validity, we conducted hypothesis testing to assess the correlation between the corresponding "pain" and "function" subscales, in addition to the "total" sum of these 2 scales, at both the baseline and follow-up. As there is no corresponding "symptoms" subscale on the PRWHE, nor an "appearance" question on the AUSCAN, these subscales were not included in the analysis as they did not purport to measure the same construct by the COSMIN definitions.
Cronbach alpha and Pearson correlation coefficients were deemed significant with a P < .01. A Cronbach alpha of 0.70 was used as the cutoff for adequate reliability. All statistics were calculated using SPSS Statistics Desktop (IMB Inc, Armonk, New York) or Microsoft Excel (Microsoft Inc, Redmond, Washington).
Results
The OA cohort consisted of 92 baseline and 83 of the baseline patients followed-up after 1.5 years, with a mean age of 56.4 years and standard deviation of 7.6 years at baseline (Table 1 ). There were near equal numbers of male and female patients (49 female, 43 male). The early OA cohort had significantly higher total AUSCAN and PRWHE scores, as well as higher scores for each of the subscales, than the asymptomatic controls at the baseline visit (P < 0.01).
The AUSCAN and PRWHE demonstrated high internal consistency (Cronbach α = 0.88-0.99) for the early OA cohort at the baseline and follow-up visits (Table 2) . Analysis of the construct validity of the pain subscale demonstrated moderate (r = 0.52−.58, P < .01) correlation between VRS pain and baseline PRWHE and AUSCAN pain and function (Table 4) .
The pain and function subscales showed low correlation with baseline key pinch and grip strength (r = −.24 to 0.33, P < .05) in our assessment of criterion validity. Hypothesis testing demonstrated a high correlation between the AUS-CAN and the PRWHE at both baseline (Table 3 ) and follow-up visits (P < .01; Table 3 ). The highest association was observed between corresponding subscales of AUSCAN and PRWHE. AUSCAN pain and PRWHE function and AUSCAN function and PRWHE pain subscales were also highly correlated. Changes in the total PRWHE correlated well to changes in the total AUSCAN (r = 0.83, P < .01), which was greater than the correlation between each of the function subscales (r = 0.71, P < .01) and the pain subscales (r = 0.56, P < .01) (Figure 1 ).
Discussion
This study compared the internal consistency, construct and criterion validity, and the correlation between the AUSCAN and PRWHE in a cohort of patients with early thumb CMC OA. As there is no gold standard to assess pain and function in CMC OA, 6 we compared the psychometric properties of 2 well-known instruments of upper extremity disability. Our work provides evidence that these instruments demonstrate similar characteristics in a population of patients with early thumb CMC OA.
Prior studies have compared the 2 measures in a more advanced CMC OA population. 23 Importantly, our study evaluated these instruments in early thumb CMC OA and over time as each individual's OA progressed; validation of these instruments during initial clinical presentation is important to guide valuable treatment decision milestones. The reported total scores of disability for PRWHE and AUSCAN in this early OA population are about half as high as other studies with more advanced OA. 23 While these patients were selected based on mild (modified Eaton 0 or I) radiographic changes, the early OA cohort still demonstrated statistically higher AUSCAN and PRWHE scores compared with controls. This supports the notion that these instruments can still distinguish early CMC OA from asymptomatic participants at this stage of the disease. These differences in baseline PRWHE and AUSCAN support the fact that patients were recruited based on a subjective history of basilar thumb pain; however, these instruments had not yet been validated for this population.
Internal consistency was high for the pain and function subscales on the AUSCAN and PRWHE, suggesting that items on each subscale consistently reproduce the same idea. High internal consistency for the total AUSCAN scale was also reported by Massy-Westropp et al. 24 Our assessment of construct validity included a comparison of selfreported pain with the VRS pain measure. These results showed no particular difference in the association between these instruments' pain and function subscales with hand strength and VRS pain measures (Table 4 ). Prior studies showed that the VRS pain measure was strongly correlated with the AUSCAN pain and function subscales 1 ; our results demonstrated similar findings with both the PRWHE and AUSCAN. To support the criterion validity of the AUS-CAN and PRWHE subscales, we compared self-reported function with objective measurements of strength; there was a low correlation between the 2 scales and hand strength, which was consistent with the results of MacDermid et al 23 that these measures were only weakly associated. The corresponding pain and function subscales of the AUSCAN and PRWHE (Tables 3 and 4 ) demonstrated the highest correlations, which are consistent with prior studies comparing the AUSCAN and PRWHE in a more advanced population of patients with CMC OA. 23 Subtle differences between constructs such as pain interference and pain intensity on a given instrument, in addition to parallels between the 2 instruments themselves, may contribute to the high correlations observed between the subscores and total scores.
These scales were also assessed in a longitudinal manner by comparing the corresponding baseline and follow-up AUSCAN and PRWHE scores. The instruments demonstrate good correlation over the 2 time points; the changes in a participant's PRWHE from baseline to follow-up were highly correlated with their changes in the AUSCAN. As the correlation between the change in an individual's AUS-CAN or PRWHE total score after 1.5 years is moderately high (r = 0.83, P < .01), this may indicate sufficient responsiveness of each to capture changes in rank order between patients. However, as the literature varies widely on the percentage of patients with early CMC OA who progress, it is difficult to assess how sensitive these instruments are to progression at this stage of the disease. This phenomenon of variability in disease progression is also evident in radiographic and biometric measurements. 17 Future studies may utilize objective strength and radiographic measurements to further assess the sensitivity of these instruments in a selected cohort of OA patients with known progression.
The strengths of this study include equal male and female population and the longitudinal nature that allows comparison at baseline and a follow-up period. Given that the age and sex distribution of our cohort matches a sample of typical patients with early CMC disease, we believe these findings are generalizable to other populations. Limitations include incomplete follow-up data on our cohort (N = 83) due to patient relocation and progression to surgery, which may result in selection bias in the cohort of less pain and disability than expected at 1.5-year follow-up. Future studies with this cohort aim to evaluate progression at over 3 years.
Conclusions
This work supports that the AUSCAN and PRWHE demonstrate equal internal consistency, construct and criterion validity, and correlate strongly with each other in this cohort of patients with early thumb CMC OA. The AUSCAN is more commonly used in studies of OA, whereas the PRWHE is used for hand surgery/rehabilitation. 4, 22, 23, 26, 28, 30 The AUS-CAN, however, is reportedly more difficult to score and has an associated annual license fee. 4, 23 This study suggests that these self-report instruments are comparable when assessing a patient with early CMC OA. The utility and feasibility of such instruments in the routine clinical setting depends on a variety of structural and patient-level factors. Further evaluation of new instruments that specifically address early thumb CMC OA, an intended future direction, will potentially assist in evaluating clinical and research utility.
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